ANALYST VIEW-Genmab 2014 operating profit above guidance

March 3 (Reuters) - Danish biotech firm Genmab reported 2014 operating income (EBIT) above its own guidance late on Monday.

Genmab (LSE: 0MGB.L - news) 's operating profit rose to 265 million Danish crowns ($40 million), up from 69 million crowns in 2013. It had previously predicted profits would come in at between 175 and 250 million crowns.

Genmab said it saw an operating profit between 200 and 275 million crowns in 2015 and revenue of between 650 and 725 million crowns.

Analysts made the following comments:

FRANK HORNING ANDERSEN, JYSKE BANK (Buy)

"Sales guidance for 2015 was slightly below our expectations while earnings outlook was better than we had expected, benefiting from a reversal of the GlaxoSmithKline (Hanover: GS7.HA - news) (GSK) liability of 175 million crowns.

"Following the report we have cut our 2015 sales forecast by 10 percent to reflect expectations of slightly lower milestone payments.

"On the other hand we have now included the reversal of the GSK liability of 175 million crowns and therefore increase our EBIT forecast from 188 million crowns to 267 million crowns."

PETER WELFORD, JEFFERIES (Buy)

"Net cash at year-end 2014 is more than sufficient as we forecast sustainable profitability with daratumumab potentially catapulting the earnings trajectory from 2016.

"Genmab's clear commitment to cost control and signing new collaborations with the three antibody tech platforms (...) could also provide future upside, which we believe is still largely underappreciated by investors."

($1 = 6.6558 Danish crowns) (Reporting by Teis Jensen, editing by Terje Solsvik)